A Multi-center, Randomized, Double-blinded, Placebo-controlled, Multiple-ascending-dose Study of Brentuximab Vedotin in Adults With Active Systemic Lupus Erythematosus
Phase of Trial: Phase II
Latest Information Update: 29 Jun 2017
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Seattle Genetics
- 23 Jun 2017 Status changed from active, no longer recruiting to discontinued.
- 30 May 2017 Planned End Date changed from 1 May 2017 to 28 Feb 2019.
- 30 May 2017 Planned primary completion date changed from 1 Apr 2017 to 27 Nov 2018.